Справка
x
Поиск
Закладки
Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Меланома кожи и слизистых оболочек
Список литературы
Поставить закладку
Clark WH, Jr., Elder DE, Guerry Dt, Epstein MN, Greene MH, Van Horn M:
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma
.
Hum Pathol
1984,
15
(12):1147-1165.
Plonka PM, Passeron T, Brenner M, Tobin DJ, Shibahara S, Thomas A, Slominski A, Kadekaro AL, Hershkovitz D, Peters E
et al
:
What are melanocytes really doing all day long...?
Exp Dermatol
2009,
18
(9):799-819.
Fitzpatrick TB:
The validity and practicality of sun-reactive skin types I through VI
.
Arch Dermatol
1988,
124
(6):869-871.
Dubin N, Pasternack BS, Moseson M:
Simultaneous assessment of risk factors for malignant melanoma and non-melanoma skin lesions, with emphasis on sun exposure and related variables
.
Int J Epidemiol
1990,
19
(4):811-819.
Carli P, Biggeri A, Nardini P, De Giorgi V, Giannotti B:
Sun exposure and large numbers of common and atypical melanocytic naevi: an analytical study in a southern European population
.
Br J Dermatol
1998,
138
(3):422-425.
Elwood JM, Koh HK:
Etiology, epidemiology, risk factors, and public health issues of melanoma
.
Curr Opin Oncol
1994,
6
(2):179-187.
Anna B, Blazej Z, Jacqueline G, Andrew CJ, Jeffrey R, Andrzej S:
Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma
.
Expert Rev Dermatol
2007,
2
(4):451-469.
Lotze TM, Dallal RM, Kirkwood JM, Flickinger JC:
Cutaneous Melanoma
. In:
Cancer: Principles and Practice of Oncology 6th edition.
edn. Edited by Devita VT, Hellman S, Rosenberg SA: Lippincott Williams & Wilkins.
Whiteman DC, Pavan WJ, Bastian BC:
The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin
.
Pigment Cell Melanoma Res
2011,
24
(5):879-897.
Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V:
Primary mucosal melanomas: a comprehensive review
.
Int J Clin Exp Pathol
2012,
5
(8):739-753.
Mahendraraj K, Lau CS, Lee I, Chamberlain RS:
Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the Surveillance, Epidemiology, and End Results database (1973-2012)
.
Clin Ophthalmol
2016,
10
:2113-2119.
Seddon J, Gragoudas E, Egan K, Polivogianis L, Finn S, Albert D:
Standardized data collection and coding in eye disease epidemiology: the Uveal Melanoma Data System
.
Ophthalmic Surg
1991,
22
(3):127-136.
Каприн АД, Старинский ВВ, Шахзадова АО (eds.):
Злокачественные новообразования в России в 2020 году (заболеваемость и смертность)
. Москва: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России,; 2021.
Каприн АД, Старинский ВВ, Шахзадова АО (eds.):
Состояние онкологической помощи населению России в 2019 году.
. Москва: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» 2020.
International Statistical Classification of Diseases and Related Health Problems 10th Revision
[
http://apps.who.int/classifications/icd10/browse/2016/en
]
Каприн АД, Старинский ВВ, Петрова ГВ (eds.):
Состояние онкологической помощи населению России в 2017 году
. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018.
Gershenwald J, Scolyer R, Hess K, al. e:
Melanoma of the skin
. In:
AJCC Cancer Staging Manual 8th ed.
edn. Edited by Amin M, Edge S, Greene F, alю e. New York: Springer International Publishing; 2017: 563-585.
Barr RG:
Foreword to the Second Set of WFUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography
.
Ultrasound Med Biol
2017,
43
(1):1-3.
Синельников ИЕ, Барышников КА, Демидов ЛВ:
КЛИНИЧЕСКАЯ ДИАГНОСТИКА МЕЛАНОМЫ КОЖИ
.
Вестник ФГБУ «РОНЦ им НН Блохина»
2017,
28
(1-2):68-73.
Grob JJ, Bonerandi JJ:
The "ugly duckling" sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening
.
Arch Dermatol
1998,
134
(1):103-104.
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, Grob JJ, Malvehy J, Newton-Bishop J, Stratigos AJ
et al
:
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016
.
Eur J Cancer
2016,
63
:201-217.
Coit DG, Thompson JA, Albertini M, Algazi A, Andtbacka R, Bichakjian C, Carson WE, 3rd, Daniels GA, DiMaio D, Fields RC
et al
:
NCCN Clinical Practice Guidelines in Oncology. Melanoma. Version 3.2018
. In
.
: National Comprehensive Cancer Network, Inc; 2018: 172.
Rat C, Grimault C, Quereux G, Dagorne M, Gaultier A, Khammari A, Dreno B, Nguyen JM:
Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study
.
BMJ Open
2015,
5
(7):e007471.
Fang P, Jiang W, Allen P, Glitza I, Guha N, Hwu P, Ghia A, Phan J, Mahajan A, Tawbi H
et al
:
Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma
.
J Neurooncol
2017,
133
(3):595-602.
Grange F:
[Multiple primary melanoma and familial melanoma. Risk evaluation and screening tests. How to evaluate the risk of developing a second melanoma? In what family? Should screening methods be implemented? Which ones and why?]
.
Ann Dermatol Venereol
1995,
122
(5):365-371.
Claeson M, Holmstrom P, Hallberg S, Gillstedt M, Gonzalez H, Wennberg AM, Paoli J:
Multiple Primary Melanomas: A Common Occurrence in Western Sweden
.
Acta Derm Venereol
2016.
Moore MM, Geller AC, Warton EM, Schwalbe J, Asgari MM:
Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011
.
J Am Acad Dermatol
2015,
73
(4):630-636.
De Giorgi V, Savarese I, D"Errico A, Gori A, Papi F, Colombino M, Sini MC, Grazzini M, Stanganelli I, Rossari S
et al
:
Epidemiological features and prognostic parameters of multiple primary melanomas in CDKN2A-mutations patients
.
Pigment Cell Melanoma Res
2015,
28
(6):747-751.
Watts CG, Dieng M, Morton RL, Mann GJ, Menzies SW, Cust AE:
Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review
.
Br J Dermatol
2015,
172
(1):33-47.
Dinnes J, Deeks JJ, Grainge MJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR, Wong KY, Aldridge RB, Abbott R
et al
:
Visual inspection for diagnosing cutaneous melanoma in adults
.
Cochrane Database of Systematic Reviews
2018(12).
Stapleton JL, Turrisi R, Mallett KA, Robinson JK:
Correspondence between pigmented lesions identified by melanoma patients trained to perform partner-assisted skin self-examination and dermatological examination
.
Cancer Epidemiol Biomarkers Prev
2015,
24
(8):1247-1253.
Duarte AF, da Costa-Pereira A, Del-Marmol V, Correia O:
Are General Physicians Prepared for Struggling Skin Cancer?-Cross-Sectional Study
.
J Cancer Educ
2016.
Ilyas M, Costello CM, Zhang N, Sharma A:
The role of the ugly duckling sign in patient education
.
J Am Acad Dermatol
2017,
77
(6):1088-1095.
Dinnes J, Deeks JJ, Grainge MJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR, Wong KY, Aldridge RB, Abbott R
et al
:
Visual inspection for diagnosing cutaneous melanoma in adults
.
Cochrane Database Syst Rev
2018,
12
:Cd013194.
Chia A, Trevena L:
A Systematic Review of Training to Improve Melanoma Diagnostic Skills in General Practitioners
.
J Cancer Educ
2016,
31
(4):730-735.
Castro LG, Messina MC, Loureiro W, Macarenco RS, Duprat Neto JP, Di Giacomo TH, Bittencourt FV, Bakos RM, Serpa SS, Stolf HO
et al
:
Guidelines of the Brazilian Dermatology Society for diagnosis, treatment and follow up of primary cutaneous melanoma--Part I
.
An Bras Dermatol
2015,
90
(6):851-861.
Dinnes J, Deeks JJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR, Wong KY, Aldridge RB, Abbott R, Fawzy M
et al
:
Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
.
Cochrane Database Syst Rev
2018,
12
:Cd011902.
Ferrante di Ruffano L, Takwoingi Y, Dinnes J, Chuchu N, Bayliss SE, Davenport C, Matin RN, Godfrey K, O"Sullivan C, Gulati A
et al
:
Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
.
Cochrane Database Syst Rev
2018,
12
:CD013186.
Menzies SW, Ingvar C, McCarthy WH:
A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma
.
Melanoma Res
1996,
6
(1):55-62.
Argenziano G, Longo C, Cameron A, Cavicchini S, Gourhant JY, Lallas A, McColl I, Rosendahl C, Thomas L, Tiodorovic-Zivkovic D
et al
:
Blue-black rule: a simple dermoscopic clue to recognize pigmented nodular melanoma
.
Br J Dermatol
2011,
165
(6):1251-1255.
Lallas A, Longo C, Manfredini M, Benati E, Babino G, Chinazzo C, Apalla Z, Papageorgiou C, Moscarella E, Kyrgidis A
et al
:
Accuracy of Dermoscopic Criteria for the Diagnosis of Melanoma In Situ
.
JAMA Dermatol
2018,
154
(4):414-419.
Longo C, Piana S, Marghoob A, Cavicchini S, Rubegni P, Cota C, Ferrara G, Cesinaro AM, Baade A, Bencini PL
et al
:
Morphological features of naevoid melanoma: results of a multicentre study of the International Dermoscopy Society
.
Br J Dermatol
2015,
172
(4):961-967.
Menzies SW, Kreusch J, Byth K, Pizzichetta MA, Marghoob A, Braun R, Malvehy J, Puig S, Argenziano G, Zalaudek I
et al
:
Dermoscopic evaluation of amelanotic and hypomelanotic melanoma
.
Arch Dermatol
2008,
144
(9):1120-1127.
Moloney FJ, Menzies SW:
Key points in the dermoscopic diagnosis of hypomelanotic melanoma and nodular melanoma
.
J Dermatol
2011,
38
(1):10-15.
Carapeba MOL, Alves Pineze M, Nai GA:
Is dermoscopy a good tool for the diagnosis of lentigo maligna and lentigo maligna melanoma? A meta-analysis
.
Clin Cosmet Investig Dermatol
2019,
12
:403-414.
Schiffner R, Schiffner-Rohe J, Vogt T, Landthaler M, Wlotzke U, Cognetta AB, Stolz W:
Improvement of early recognition of lentigo maligna using dermatoscopy
.
J Am Acad Dermatol
2000,
42
(1 Pt 1):25-32.
Koga H, Saida T:
Revised 3-step dermoscopic algorithm for the management of acral melanocytic lesions
.
Arch Dermatol
2011,
147
(6):741-743.
Koga H, Saida T, Uhara H:
Key point in dermoscopic differentiation between early nail apparatus melanoma and benign longitudinal melanonychia
.
J Dermatol
2011,
38
(1):45-52.
Phan A, Dalle S, Touzet S, Ronger-Savle S, Balme B, Thomas L:
Dermoscopic features of acral lentiginous melanoma in a large series of 110 cases in a white population
.
Br J Dermatol
2010,
162
(4):765-771.
Adler NR, Kelly JW, Guitera P, Menzies SW, Chamberlain AJ, Fishburn P, Button-Sloan AE, Heal C, Soyer HP, Thompson JF:
Methods of melanoma detection and of skin monitoring for individuals at high risk of melanoma: new Australian clinical practice
.
Med J Aust
2019,
210
(1):41-47.
Tschandl P, Hofmann L, Fink C, Kittler H, Haenssle HA:
Melanomas vs. nevi in high-risk patients under long-term monitoring with digital dermatoscopy: do melanomas and nevi already differ at baseline?
J Eur Acad Dermatol Venereol
2017,
31
(6):972-977.
Watts CG, Wortley S, Norris S, Menzies SW, Guitera P, Askie L, Mann GJ, Morton RL, Cust AE:
A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia
.
Appl Health Econ Health Policy
2018,
16
(2):235-242.
Ferrante di Ruffano L, Takwoingi Y, Dinnes J, Chuchu N, Bayliss SE, Davenport C, Matin RN, Godfrey K, O"Sullivan C, Gulati A
et al
:
Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
.
Cochrane Database Syst Rev
2018,
12
:Cd013186.
Giavedoni P, Ririe M, Carrera C, Puig S, Malvehy J:
Familial Melanoma Associated with Li-Fraumeni Syndrome and Atypical Mole Syndrome: Total-body Digital Photography, Dermoscopy and Confocal Microscopy
.
Acta Derm Venereol
2017,
97
(6):720-723.
Kittler H, Guitera P, Riedl E, Avramidis M, Teban L, Fiebiger M, Weger RA, Dawid M, Menzies S:
Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging
.
Arch Dermatol
2006,
142
(9):1113-1119.
Rinner C, Tschandl P, Sinz C, Kittler H:
Long-term evaluation of the efficacy of digital dermatoscopy monitoring at a tertiary referral center
.
J Dtsch Dermatol Ges
2017,
15
(5):517-522.
Robinson JK, Nickoloff BJ:
Digital epiluminescence microscopy monitoring of high-risk patients
.
Arch Dermatol
2004,
140
(1):49-56.
Berk-Krauss J, Polsky D, Stein JA:
Mole Mapping for Management of Pigmented Skin Lesions
.
Dermatol Clin
2017,
35
(4):439-445.
Truong A, Strazzulla L, March J, Boucher KM, Nelson KC, Kim CC, Grossman D:
Reduction in nevus biopsies in patients monitored by total body photography
.
J Am Acad Dermatol
2016,
75
(1):135-143 e135.
Inskip M, Magee J, Weedon D, Rosendahl C:
When algorithms falter: a case report of a very small melanoma excised due to the dermatoscopic "ugly duckling" sign
.
Dermatol Pract Concept
2013,
3
(2):59-62.
Akay BN, Okcu Heper A, Clark S, Erdem C, Rosendahl CO, Kittler H:
Dermatoscopy of a melanoma less than one millimeter in diameter
.
Int J Dermatol
2017,
56
(12):1498-1499.
Bafounta ML, Beauchet A, Chagnon S, Saiag P:
Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis
.
Lancet Oncol
2004,
5
(11):673-680.
Farberg AS, Rigel DS:
A comparison of current practice patterns of US dermatologists versus published guidelines for the biopsy, initial management, and follow up of patients with primary cutaneous melanoma
.
J Am Acad Dermatol
2016,
75
(6):1193-1197 e1191.
Weinstock MA, Lott JP, Wang Q, Titus LJ, Onega T, Nelson HD, Pearson L, Piepkorn M, Elmore JG, Tosteson AN:
Skin Biopsy Utilization and Melanoma Incidence among Medicare Beneficiaries
.
Br J Dermatol
2016.
Rayess HM, Gupta A, Svider PF, Raza SN, Shkoukani M, Zuliani GF, Carron MA:
A critical analysis of melanoma malpractice litigation: Should we biopsy everything?
Laryngoscope
2017,
127
(1):134-139.
Moscarella E, Argenziano G, Moreno C, Piana S, Lallas A, Lombardi M, Longo C, Ferrara G:
Intralesional (incision) biopsy for melanoma diagnosis: the rules and the exception to the rules
.
G Ital Dermatol Venereol
2016.
Bolshinsky V, Lin MJ, Serpell J, Leung M, Wolfe R, McLean C, Kelly JW:
Frequency of residual melanoma in wide local excision (WLE) specimens after complete excisional biopsy
.
J Am Acad Dermatol
2016,
74
(1):102-107.
Luk PP, Vilain R, Crainic O, McCarthy SW, Thompson JF, Scolyer RA:
Punch biopsy of melanoma causing tumour cell implantation: another peril of utilising partial biopsies for melanocytic tumours
.
Australas J Dermatol
2015,
56
(3):227-231.
Soltani-Arabshahi R, Sweeney C, Jones B, Florell SR, Hu N, Grossman D:
Predictive value of biopsy specimens suspicious for melanoma: support for 6-mm criterion in the ABCD rule
.
J Am Acad Dermatol
2015,
72
(3):412-418.
Mills JK, White I, Diggs B, Fortino J, Vetto JT:
Effect of biopsy type on outcomes in the treatment of primary cutaneous melanoma
.
Am J Surg
2013,
205
(5):585-590; discussion 590.
de Lecea MV, Palomares T, Al Kassam D, Cavia M, Geh JL, de Llano P, Muniz P, Armesto D, Martinez-Indart L, Alonso-Varona A:
Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B
.
J Eur Acad Dermatol Venereol
2016.
Nikolin B, Djan I, Trifunovic J, Dugandzija T, Novkovic D, Djan V, Vucinic N:
MIA, S100 and LDH as important predictors of overall survival of patients with stage IIb and IIc melanoma
.
J BUON
2016,
21
(3):691-697.
Wevers KP, Kruijff S, Speijers MJ, Bastiaannet E, Muller Kobold AC, Hoekstra HJ:
S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma
.
Ann Surg Oncol
2013,
20
(8):2772-2779.
Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A:
Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma
.
Eur J Cancer
2012,
48
(5):695-702.
Egberts F, Momkvist A, Egberts JH, Kaehler KC, Hauschild A:
Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients
.
Anticancer Res
2010,
30
(5):1799-1805.
Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, Stein CA, Itri LM, Suciu S, Eggermont AM:
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
.
Eur J Cancer
2009,
45
(10):1807-1814.
Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A:
Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH
.
Onkologie
2008,
31
(7):380-384.
Zhan H, Ma JY, Jian QC:
Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis
.
Clin Chim Acta
2018,
484
:136-140.
Gao D, Ma X:
Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma
.
Panminerva Med
2017,
59
(4):332-337.
Leiter U, Buettner PG, Eigentler TK, Forschner A, Meier F, Garbe C:
Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?
Melanoma Res
2010,
20
(3):240-246.
Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, Giles GG, Wallace AB, Anderson PR, Guiver TA
et al
:
Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians
.
BMJ
2013,
346
:f2360.
Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN:
Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis
.
Surg Oncol
2014,
23
(1):11-16.
Podlipnik S, Carrera C, Sanchez M, Arguis P, Olondo ML, Vilana R, Rull R, Vidal-Sicart S, Vilalta A, Conill C
et al
:
Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study
.
J Am Acad Dermatol
2016,
75
(3):516-524.
Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB:
Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines
.
J Clin Oncol
2010,
28
(18):3042-3047.
Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JN:
Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis
.
J Natl Cancer Inst
2011,
103
(2):129-142.
Dinnes J, Ferrante di Ruffano L, Takwoingi Y, Cheung ST, Nathan P, Matin RN, Chuchu N, Chan SA, Durack A, Bayliss SE
et al
:
Ultrasound, CT, MRI, or PET‐CT for staging and re‐staging of adults with cutaneous melanoma
.
Cochrane Database of Systematic Reviews
2019(7).
Lazaga FJ, Oz OK, Adams-Huet B, Anderson J, Mathews D:
Comparison of whole-body versus limited whole-body 18F-FDG PET/CT scan in malignant cutaneous melanoma
.
Clin Nucl Med
2013,
38
(11):882-884.
Ortega-Candil A, Rodriguez-Rey C, Cano-Carrizal R, Cala-Zuluaga E, Gonzalez Larriba JL, Jimenez-Ballve A, Fuentes-Ferrer ME, Cabrera-Martin MN, Perez-Castejon MJ, Garcia Garcia-Esquinas M
et al
:
Breslow thickness and (18)F-FDG PET-CT result in initial staging of cutaneous melanoma: Can a cut-off point be established?
Rev Esp Med Nucl Imagen Mol
2016,
35
(2):96-101.
Sanchez-Sanchez R, Serrano-Falcon C, Rebollo Aguirre AC:
Diagnostic imaging in dermatology: utility of PET-CT in cutaneous melanoma
.
Actas Dermosifiliogr
2015,
106
(1):29-34.
Jouvet JC, Thomas L, Thomson V, Yanes M, Journe C, Morelec I, Bracoud L, Durupt F, Giammarile F, Berthezene Y:
Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study
.
J Eur Acad Dermatol Venereol
2014,
28
(2):176-185.
Gjorup CA, Hendel HW, Pilegaard RK, Willert CB, Holmich LR:
Routine X-ray of the chest is not justified in staging of cutaneous melanoma patients
.
Dan Med J
2016,
63
(12).
Aukema TS, Valdes Olmos RA, Wouters MW, Klop WM, Kroon BB, Vogel WV, Nieweg OE:
Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases
.
Ann Surg Oncol
2010,
17
(10):2773-2778.
Aukema TS, Olmos RA, Korse CM, Kroon BB, Wouters MW, Vogel WV, Bonfrer JM, Nieweg OE:
Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up
.
Ann Surg Oncol
2010,
17
(6):1657-1661.
Tas F, Erturk K:
Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors
.
Melanoma Res
2017.
Suh CH, Jung SC, Kim KW, Pyo J:
The detectability of brain metastases using contrast-enhanced spin-echo or gradient-echo images: a systematic review and meta-analysis
.
J Neurooncol
2016,
129
(2):363-371.
Wang S, Sun S, Liu X, Ge N, Wang G, Guo J, Liu W, Wang S:
Endoscopic diagnosis of primary anorectal melanoma
.
Oncotarget
2017,
8
(30):50133-50140.
Pflugfelder A, Weide B, Eigentler TK, Forschner A, Leiter U, Held L, Meier F, Garbe C:
Incisional biopsy and melanoma prognosis: Facts and controversies
.
Clin Dermatol
2010,
28
(3):316-318.
Wheatley K, Wilson JS, Gaunt P, Marsden JR:
Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation
.
Cancer Treat Rev
2016,
42
:73-81.
Wheatley K, Wilson JS, Gaunt P, Marsden JR:
Reply to response to Wheatley et al., "Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation" Cancer Treatment Reviews April 2016;45:76
.
Cancer Treat Rev
2016.
Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, Bufalino R, Craig P, De Marsillac J, Durand JC
et al
:
Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm
.
N Engl J Med
1988,
318
(18):1159-1162.
Ringborg U, Andersson R, Eldh J, Glaumann B, Hafstrom L, Jacobsson S, Jonsson PE, Johansson H, Krysander L, Lagerlof B:
Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group
.
Cancer
1996,
77
(9):1809-1814.
Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson H, Jonsson PE, Krysander L, Lindholm C, Ringborg U:
Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm
.
Cancer
2000,
89
(7):1495-1501.
Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, Jewell WR, Bartolucci AA, Mihm MC, Jr., Barnhill R
et al
:
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial
.
Ann Surg
1993,
218
(3):262-267; discussion 267-269.
Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, Temple WJ, Mihm MC, Barnhill RL, Jewell WR
et al
:
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas
.
Ann Surg Oncol
2001,
8
(2):101-108.
Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex JA, Lauret P, Verola O, Auclerc G, Harper P
et al
:
Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick)
.
Cancer
2003,
97
(8):1941-1946.
Thomas JM, Newton-Bishop J, A"Hern R, Coombes G, Timmons M, Evans J, Cook M, Theaker J, Fallowfield M, O"Neill T
et al
:
Excision margins in high-risk malignant melanoma
.
N Engl J Med
2004,
350
(8):757-766.
Gillgren P, Drzewiecki KT, Niin M, Gullestad HP, Hellborg H, Mansson-Brahme E, Ingvar C, Ringborg U:
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial
.
Lancet
2011,
378
(9803):1635-1642.
Breslow A:
Prognosis in cutaneous melanoma: tumor thickness as a guide to treatment
.
Pathol Annu
1980,
15
(Pt 1):1-22.
Breslow A:
Melanoma thickness and elective node dissection
.
Arch Dermatol
1978,
114
(9):1399.
Breslow A:
Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma
.
Ann Surg
1975,
182
(5):572-575.
Breslow A:
Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma
.
Ann Surg
1970,
172
(5):902-908.
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM
et al
:
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases
.
J Clin Oncol
2010,
28
(14):2452-2459.
Gershenwald JE, Soong SJ, Balch CM, American Joint Committee on Cancer Melanoma Staging C:
2010 TNM staging system for cutaneous melanoma...and beyond
.
Ann Surg Oncol
2010,
17
(6):1475-1477.
Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, Gimotty P, Force AMT:
Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database
.
Ann Surg Oncol
2010,
17
(8):2006-2014.
Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr., Kirkwood JM
et al
:
An evidence-based staging system for cutaneous melanoma
.
CA Cancer J Clin
2004,
54
(3):131-149; quiz 182-134.
Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA:
The prognostic significance of ulceration of cutaneous melanoma
.
Cancer
1980,
45
(12):3012-3017.
Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA:
A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma
.
Surgery
1979,
86
(2):343-351.
Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA:
A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark"s and Breslow"s staging methods
.
Ann Surg
1978,
188
(6):732-742.
Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U, Committee EG:
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
.
Ann Oncol
2015,
26 Suppl 5
:v126-132.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W
et al
:
Mutations of the BRAF gene in human cancer
.
Nature
2002,
417
(6892):949-954.
Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V
et al
:
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
.
Lancet Oncol
2015,
16
(13):1389-1398.
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Jr., Kaempgen E
et al
:
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
.
Lancet
2012,
380
(9839):358-365.
Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J
et al
:
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
.
J Clin Oncol
2016.
McGettigan S:
Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma
.
J Adv Pract Oncol
2014,
5
(3):211-215.
Daud A, Pavlick AC, Ribas A, Gonzalez R, Lewis KD, Hamid O, Gajewski T, Puzanov I, Hsu JJ, Koralek DO
et al
:
Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma
.
J Clin Oncol
2016,
34
(suppl; abstr 9510).
Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L
et al
:
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma
.
N Engl J Med
2014,
371
(20):1867-1876.
Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K
et al
:
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study
.
Lancet Oncol
2014,
15
(9):954-965.
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R
et al
:
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
.
Lancet Oncol
2018.
Kim S, Kim HT, Suh HS:
Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis
.
J Dermatolog Treat
2018,
29
(3):314-321.
Devji T, Levine O, Neupane B, Beyene J, Xie F:
Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials
.
JAMA Oncol
2017,
3
(3):366-373.
Abu-Abed S, Pennell N, Petrella T, Wright F, Seth A, Hanna W:
KIT gene mutations and patterns of protein expression in mucosal and acral melanoma
.
J Cutan Med Surg
2012,
16
(2):135-142.
Abysheva SN, Iyevleva AG, Efimova NV, Mokhina YB, Sabirova FA, Ivantsov AO, Artemieva AS, Togo AV, Moiseyenko VM, Matsko DE
et al
:
KIT mutations in Russian patients with mucosal melanoma
.
Melanoma Res
2011,
21
(6):555-559.
Allegra M, Giacchero D, Segalen C, Dumaz N, Butori C, Hofman V, Hofman P, Lacour JP, Bertolotto C, Bahadoran P
et al
:
A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib
.
J Invest Dermatol
2014,
134
(5):1473-1476.
Bastian BC, Esteve-Puig R:
Targeting activated KIT signaling for melanoma therapy
.
J Clin Oncol
2013,
31
(26):3288-3290.
Becker JC, Brocker EB, Schadendorf D, Ugurel S:
Imatinib in melanoma: a selective treatment option based on KIT mutation status?
J Clin Oncol
2007,
25
(7):e9.
Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J
et al
:
KIT as a therapeutic target in metastatic melanoma
.
JAMA
2011,
305
(22):2327-2334.
Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD
et al
:
Major response to imatinib mesylate in KIT-mutated melanoma
.
J Clin Oncol
2008,
26
(12):2046-2051.
Dumaz N, Andre J, Sadoux A, Laugier F, Podgorniak MP, Mourah S, Lebbe C:
Driver KIT mutations in melanoma cluster in four hotspots
.
Melanoma Res
2015,
25
(1):88-90.
Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P
et al
:
BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma
.
J Cutan Pathol
2012,
39
(9):821-825.
Lv J, Kong Y, Cai X, Zhou X:
Analysis of KIT and BRAF mutations in Chinese melanoma
.
Pathology
2016,
48 Suppl 1
:S140.
Lyu J, Wu Y, Li C, Wang R, Song H, Ren G, Guo W:
Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases
.
J Oral Pathol Med
2016,
45
(4):295-301.
McDonnell K, Betz B, Fullen D, Lao CD:
V559A and N822I double KIT mutant melanoma with predictable response to imatinib?
Pigment Cell Melanoma Res
2011,
24
(2):390-392.
Rapisuwon S, Parks K, Al-Refaie W, Atkins MB:
Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report
.
Melanoma Res
2014,
24
(5):509-511.
Zebary A, Omholt K, Vassilaki I, Hoiom V, Linden D, Viberg L, Kanter-Lewensohn L, Johansson CH, Hansson J:
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma
.
J Dermatol Sci
2013,
72
(3):284-289.
Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF
et al
:
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin
.
J Clin Oncol
2013,
31
(26):3182-3190.
Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI
et al
:
Phase II trial of imatinib mesylate in patients with metastatic melanoma
.
Br J Cancer
2008,
99
(5):734-740.
Kalinsky K, Lee S, Rubin KM, Lawrence DP, Iafrarte AJ, Borger DR, Margolin KA, Leitao MM, Jr., Tarhini AA, Koon HB
et al
:
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)
.
Cancer
2017,
123
(14):2688-2697.
Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C
et al
:
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial
.
Ann Oncol
2017,
28
(6):1380-1387.
Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X
et al
:
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification
.
J Clin Oncol
2011,
29
(21):2904-2909.
Guo J, Qin S, Liang J, Lin T, Si L, Chen X, Chi Z, Cui C, Du N, Fan Y
et al
:
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
.
Chin Clin Oncol
2016,
5
(4):57.
Stage I melanoma of the skin: the problem of resection margins. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma
.
Eur J Cancer
1980,
16
(8):1079-1085.
Shelley W, Kersey P, Quirt I, Pater J:
Survey of surgical management of malignant melanoma in Canada: optimal margins of excision and lymph-node dissection
.
Can J Surg
1984,
27
(2):190-192.
Demidov LV, Martynova EV:
[Retrospective evaluation of the safe reduction of surgical margins of resected stage-IIA cutaneous melanoma of the trunk and extremities]
.
Vopr Onkol
2002,
48
(1):68-73.
Lens MB, Newton-Bishop JA, Dawes M:
Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick)
.
Cancer
2004,
100
(2):433-434; author reply 434.
Thompson JF, Scolyer RA, Uren RF:
Surgical management of primary cutaneous melanoma: excision margins and the role of sentinel lymph node examination
.
Surg Oncol Clin N Am
2006,
15
(2):301-318.
Mocellin S, Pasquali S, Nitti D:
The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins
.
Ann Surg
2011,
253
(2):238-243.
Duffy KL, Truong A, Bowen GM, Andtbacka RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR
et al
:
Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ
.
J Am Acad Dermatol
2014,
71
(4):835-838.
Koskivuo I, Giordano S, Verajankorva E, Vihinen P:
One-cm Versus 2-cm Excision Margins for Patients With Intermediate Thickness Melanoma: A Matched-Pair Analysis
.
Dermatol Surg
2015,
41
(10):1130-1136.
Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A
et al
:
Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases
.
Ann Surg Oncol
2017,
24
(13):3991-4000.
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ
et al
:
Final trial report of sentinel-node biopsy versus nodal observation in melanoma
.
N Engl J Med
2014,
370
(7):599-609.
Felton S, Taylor RS, Srivastava D:
Excision Margins for Melanoma In Situ on the Head and Neck
.
Dermatol Surg
2016,
42
(3):327-334.
Rawlani R, Rawlani V, Qureshi HA, Kim JY, Wayne JD:
Reducing margins of wide local excision in head and neck melanoma for function and cosmesis: 5-year local recurrence-free survival
.
J Surg Oncol
2015,
111
(7):795-799.
Moehrle M, Metzger S, Schippert W, Garbe C, Rassner G, Breuninger H:
"Functional" surgery in subungual melanoma
.
Dermatol Surg
2003,
29
(4):366-374.
Pockaj BA, Jaroszewski DE, DiCaudo DJ, Hentz JG, Buchel EW, Gray RJ, Markovic SN, Bite U:
Changing surgical therapy for melanoma of the external ear
.
Ann Surg Oncol
2003,
10
(6):689-696.
Farshad A, Burg G, Panizzon R, Dummer R:
A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays
.
Br J Dermatol
2002,
146
(6):1042-1046.
Harwood AR:
Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma
.
Int J Radiat Oncol Biol Phys
1983,
9
(7):1019-1021.
Hedblad MA, Mallbris L:
Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma
.
J Am Acad Dermatol
2012,
67
(1):60-68.
Chen JY, Hruby G, Scolyer RA, Murali R, Hong A, Fitzgerald P, Pham TT, Quinn MJ, Thompson JF:
Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases
.
Cancer
2008,
113
(10):2770-2778.
Christie DR, Tiver KV:
Radiotherapy for melanotic freckles
.
Austral Radiol
1996,
40
:331-333.
Testori A, Soteldo J, Powell B, Sales F, Borgognoni L, Rutkowski P, Lejeune F, van Leeuwen P, Eggermont A:
Surgical management of melanoma: an EORTC Melanoma Group survey
.
Ecancermedicalscience
2013,
7
:294.
Lens MB, Dawes M, Goodacre T, Newton-Bishop JA:
Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials
.
Arch Surg
2002,
137
(4):458-461.
Yonick DV, Ballo RM, Kahn E, Dahiya M, Yao K, Godellas C, Shoup M, Aranha GV:
Predictors of positive sentinel lymph node in thin melanoma
.
Am J Surg
2011,
201
(3):324-327; discussion 327-328.
Cascinelli N, Belli F, Santinami M, Fait V, Testori A, Ruka W, Cavaliere R, Mozzillo N, Rossi CR, MacKie RM
et al
:
Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience
.
Ann Surg Oncol
2000,
7
(6):469-474.
Stoffels I, Dissemond J, Poppel T, Schadendorf D, Klode J:
Intraoperative Fluorescence Imaging for Sentinel Lymph Node Detection: Prospective Clinical Trial to Compare the Usefulness of Indocyanine Green vs Technetium Tc 99m for Identification of Sentinel Lymph Nodes
.
JAMA Surg
2015,
150
(7):617-623.
de Bree E, de Bree R:
Implications of the MSLT-1 for sentinel lymph node biopsy in cutaneous head and neck melanoma
.
Oral Oncol
2015,
51
(7):629-633.
van Akkooi AC, Eggermont AM:
Melanoma: MSLT-1--SNB is a biomarker, not a therapeutic intervention
.
Nat Rev Clin Oncol
2014,
11
(5):248-249.
Ross MI, Gershenwald JE:
How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?
Ann Surg Oncol
2008,
15
(3):670-673.
Morton DL:
Intraoperative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation?
Cancer J Sci Am
1997,
3
(6):328-330.
Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ
et al
:
Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial
.
Ann Surg
2005,
242
(3):302-311; discussion 311-303.
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD
et al
:
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
.
N Engl J Med
2017,
376
(23):2211-2222.
Bostick PJ, Morton DL, Turner RR, Huynh KT, Wang HJ, Elashoff R, Essner R, Hoon DS:
Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients
.
J Clin Oncol
1999,
17
(10):3238-3244.
van der Velde-Zimmermann D, Schipper ME, de Weger RA, Hennipman A, Borel Rinkes IH:
Sentinel node biopsies in melanoma patients: a protocol for accurate, efficient, and cost-effective analysis by preselection for immunohistochemistry on the basis of Tyr-PCR
.
Ann Surg Oncol
2000,
7
(1):51-54.
Eggermont AM, Keilholz U, Testori A, Cook M, Lienard D, Ruiter DJ:
The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer
.
Ann Surg Oncol
2001,
8
(9 Suppl):38S-40S.
Spanknebel K, Coit DG, Bieligk SC, Gonen M, Rosai J, Klimstra DS:
Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis
.
Am J Surg Pathol
2005,
29
(3):305-317.
Laga AC, Zhan Q, Weishaupt C, Ma J, Frank MH, Murphy GF:
SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study
.
Exp Dermatol
2011,
20
(4):339-345.
Lee JJ, Granter SR, Laga AC, Saavedra AP, Zhan Q, Guo W, Xu S, Murphy GF, Lian CG:
5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies
.
Mod Pathol
2015,
28
(2):218-229.
Chen PL, Chen WS, Li J, Lind AC, Lu D:
Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas
.
Mod Pathol
2013,
26
(1):44-53.
Satzger I, Volker B, Meier A, Schenck F, Kapp A, Gutzmer R:
Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes
.
Am J Surg Pathol
2007,
31
(8):1175-1180.
Scolyer RA, Judge MJ, Evans A, Frishberg DP, Prieto VG, Thompson JF, Trotter MJ, Walsh MY, Walsh NM, Ellis DW
et al
:
Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR)
.
Am J Surg Pathol
2013,
37
(12):1797-1814.
Shidham VB, Qi D, Rao RN, Acker SM, Chang CC, Kampalath B, Dawson G, Machhi JK, Komorowski RA:
Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with "MCW melanoma cocktail"--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase
.
BMC Cancer
2003,
3
:15.
Murray CA, Leong WL, McCready DR, Ghazarian DM:
Histopathological patterns of melanoma metastases in sentinel lymph nodes
.
J Clin Pathol
2004,
57
(1):64-67.
Vitoux D, Mourah S, Kerob D, Verola O, Basset-Seguin N, Baccard M, Schartz N, Ollivaud L, Archimbaud A, Servant JM
et al
:
Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases
.
Arch Dermatol
2009,
145
(10):1105-1113.
Rimoldi D, Lemoine R, Kurt AM, Salvi S, Berset M, Matter M, Roche B, Cerottini JP, Guggisberg D, Krischer J
et al
:
Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods
.
Melanoma Res
2003,
13
(5):511-520.
Baisden BL, Askin FB, Lange JR, Westra WH:
HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma
.
Am J Surg Pathol
2000,
24
(8):1140-1146.
Lukowsky A, Bellmann B, Ringk A, Winter H, Audring H, Fenske S, Sterry W:
Detection of melanoma micrometastases in the sentinel lymph node and in nonsentinel nodes by tyrosinase polymerase chain reaction
.
J Invest Dermatol
1999,
113
(4):554-559.
Voit CA, Oude Ophuis CM, Ulrich J, van Akkooi AC, Eggermont AM:
Ultrasound of the sentinel node in melanoma patients: echo-free island is a discriminatory morphologic feature for node positivity
.
Melanoma Res
2016,
26
(3):267-271.
Voit CA, Gooskens SL, Siegel P, Schaefer G, Schoengen A, Rowert J, van Akkooi AC, Eggermont AM:
Ultrasound-guided fine needle aspiration cytology as an addendum to sentinel lymph node biopsy can perfect the staging strategy in melanoma patients
.
Eur J Cancer
2014,
50
(13):2280-2288.
Voit CA, van Akkooi AC, Schafer-Hesterberg G, Schoengen A, Schmitz PI, Sterry W, Eggermont AM:
Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?
J Clin Oncol
2009,
27
(30):4994-5000.
Voit C, Schoengen A, Schwurzer-Voit M, Weber L, Ulrich J, Sterry W, Proebstle TM:
The role of ultrasound in detection and management of regional disease in melanoma patients
.
Semin Oncol
2002,
29
(4):353-360.
АЛЛАХВЕРДЯН ГС, ЧЕКАЛОВА МА, КОКОСАДЗЕ НВ:
ВОЗМОЖНОСТИ УЛЬТРАЗВУКОВОГО ИССЛЕДОВАНИЯ В РАННЕЙ ДИАГНОСТИКЕ МЕТАСТАЗОВ МЕЛАНОМЫ КОЖИ В РЕГИОНАРНЫХ ЛИМФАТИЧЕСКИХ УЗЛАХ
.
ДИАГНОСТИЧЕСКАЯ И ИНТЕРВЕНЦИОННАЯ РАДИОЛОГИЯ
2013,
7
(4-4):9-14.
Torabi SJ, Benchetrit L, Spock T, Cheraghlou S, Judson BL:
Clinically node-negative head and neck mucosal melanoma: An analysis of current treatment guidelines & outcomes
.
Oral Oncol
2019,
92
:67-76.
Ramesh M, Nanda S, Misra B:
Mucosal melanoma of the head-and-neck region: A single institutional clinical experience
.
South Asian J Cancer
2019,
8
(1):26.
Prinzen T, Klein M, Hallermann C, Wermker K:
Primary head and neck mucosal melanoma: Predictors of survival and a case series on sentinel node biopsy
.
J Craniomaxillofac Surg
2019.
Moya-Plana A, Mangin D, Dercle L, Taouachi R, Casiraghi O, Ammari S, Nguyen F, Temam S, Robert C, Gorphe P:
Risk-based stratification in head and neck mucosal melanoma
.
Oral Oncol
2019,
97
:44-49.
Yao JJ, Zhang F, Zhang GS, Deng XW, Zhang WJ, Lawrence WR, Zou L, Zhang XS, Lu LX:
Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study
.
Cancer Manag Res
2018,
10
:6985-6996.
Comoglu S, Polat B, Celik M, Sahin B, Enver N, Keles MN, Sari SO:
Prognostic factors in head and neck mucosal malignant melanoma
.
Auris Nasus Larynx
2018,
45
(1):135-142.
Игнатова АВ, Мудунов АМ, Подвязников СО:
Особенности клинического течения меланомы слизистых оболочек головы и шеи. обзор литературы
.
Опухоли головы и шеи
2015,
5
(4):48-52.
Amit M, Tam S, Abdelmeguid AS, Roberts DB, Raza SM, Su SY, Kupferman ME, DeMonte F, Hanna EY:
Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma
.
Cancer
2018,
124
(3):514-520.
Clark RR, Shoaib T:
Sentinel lymph node biopsy: a new perspective in head and neck mucosal melanoma?
Melanoma Res
2007,
17
(1):59.
Francisco AL, Furlan MV, Peresi PM, Nishimoto IN, Lourenco SV, Pinto CA, Kowalski LP, Ikeda MK:
Head and neck mucosal melanoma: clinicopathological analysis of 51 cases treated in a single cancer centre and review of the literature
.
Int J Oral Maxillofac Surg
2016,
45
(2):135-140.
Green B, Elhamshary A, Gomez R, Rahimi S, Brennan PA:
An update on the current management of head and neck mucosal melanoma
.
J Oral Pathol Med
2017,
46
(7):475-479.
Loree TR, Mullins AP, Spellman J, North JH, Jr., Hicks WL, Jr.:
Head and neck mucosal melanoma: a 32-year review
.
Ear Nose Throat J
1999,
78
(5):372-375.
Lourenco SV, Fernandes JD, Hsieh R, Coutinho-Camillo CM, Bologna S, Sangueza M, Nico MM:
Head and neck mucosal melanoma: a review
.
Am J Dermatopathol
2014,
36
(7):578-587.
Luna-Ortiz K, Villavicencio-Valencia V, Martinez Said H:
Comparative study of head and neck mucosal melanoma in 66 patients vs 226 patients with cutaneous melanoma: A survival analysis
.
Clin Otolaryngol
2018,
43
(2):691-696.
Meleti M, Leemans CR, de Bree R, Vescovi P, Sesenna E, van der Waal I:
Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy
.
Head Neck
2008,
30
(12):1543-1551.
Diller ML, Martin BM, Delman KA:
Lymph node dissection for stage III melanoma
.
Surg Oncol Clin N Am
2015,
24
(2):261-277.
Mozzillo N, Caraco C, Marone U, Di Monta G, Crispo A, Botti G, Montella M, Ascierto PA:
Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors
.
World J Surg Oncol
2013,
11
:36.
Galliot-Repkat C, Cailliod R, Trost O, Danino A, Collet E, Lambert D, Vabres P, Dalac S:
The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma
.
Eur J Surg Oncol
2006,
32
(7):790-794.
Hughes TM, Thomas JM:
Combined inguinal and pelvic lymph node dissection for stage III melanoma
.
Br J Surg
1999,
86
(12):1493-1498.
Shen P, Conforti AM, Essner R, Cochran AJ, Turner RR, Morton DL:
Is the node of Cloquet the sentinel node for the iliac/obturator node group?
Cancer J
2000,
6
(2):93-97.
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S
et al
:
Final version of 2009 AJCC melanoma staging and classification
.
J Clin Oncol
2009,
27
(36):6199-6206.
Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U:
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma
.
Clin Cancer Res
2004,
10
(5):1670-1677.
Petrella T:
Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommendations 2009
. In:
Evidence-based Series #8-1 Version 32009: Section 1.
2009.
Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH:
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190
.
J Clin Oncol
2000,
18
(12):2444-2458.
Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U:
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801
.
J Clin Oncol
2001,
19
(9):2370-2380.
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH:
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684
.
J Clin Oncol
1996,
14
(1):7-17.
Wheatley K, Ives N, Eggermont A, Kirkwood J, Cascinelli N, Markovic SN, Hancock B, Lee S, Suciu S, on behalf of International Malignant Melanoma Collaborative Group:
Interferon-{alpha} as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials
.
ASCO Meeting Abstracts
2007,
25
(18_suppl):8526.
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS
et al
:
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
.
N Engl J Med
2018,
378
(19):1789-1801.
Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A
et al
:
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
.
N Engl J Med
2017,
377
(19):1813-1823.
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I
et al
:
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
.
N Engl J Med
2017,
377
(19):1824-1835.
Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S
et al
:
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial
.
Lancet Oncol
2012,
13
(6):589-597.
Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S
et al
:
Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial
.
Lancet Oncol
2015,
16
(9):1049-1060.
Beadle BM, Guadagnolo BA, Ballo MT, Lee JE, Gershenwald JE, Cormier JN, Mansfield PF, Ross MI, Zagars GK:
Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma
.
Int J Radiat Oncol Biol Phys
2009,
73
(5):1376-1382.
Bibault JE, Dewas S, Mirabel X, Mortier L, Penel N, Vanseymortier L, Lartigau E:
Adjuvant radiation therapy in metastatic lymph nodes from melanoma
.
Radiat Oncol
2011,
6
:12.
Adams G, Foote M, Brown S, Burmeister B:
Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques
.
Melanoma Res
2017,
27
(1):50-56.
Mattes MD, Zhou Y, Berry SL, Barker CA:
Dosimetric comparison of axilla and groin radiotherapy techniques for high-risk and locally advanced skin cancer
.
Radiat Oncol J
2016,
34
(2):145-155.
Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, JanJan N, Lipsett J:
Fraction size in external beam radiation therapy in the treatment of melanoma
.
Int J Radiat Oncol Biol Phys
1991,
20
(3):429-432.
Sobin LH, Gospodarowicz MK, Wittekind C (eds.):
The TNM classification of malignant tumours 8th edition
, 8th edn: Wiley-Blackwell; 2009.
Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, Mackie R
et al
:
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
.
Lancet
2008,
372
(9633):117-126.
Mocellin S, Pasquali S, Rossi CR, Nitti D:
Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis
.
J Natl Cancer Inst
2010,
102
(7):493-501.
Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, Garbe C, Wheatley K, International Melanoma Meta-Analysis Collaborative G:
Adjuvant interferon-alpha for the treatment of high-risk melanoma: An individual patient data meta-analysis
.
Eur J Cancer
2017,
82
:171-183.
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV
et al
:
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
.
Lancet
2022.
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV
et al
:
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
.
Lancet
2022,
399
(10336):1718-1729.
Lala M, Li TR, de Alwis DP, Sinha V, Mayawala K, Yamamoto N, Siu LL, Chartash E, Aboshady H, Jain L:
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
.
Eur J Cancer
2020,
131
:68-75.
Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Aubock J, Fritsch P, Kerl H
et al
:
Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group
.
J Clin Oncol
1998,
16
(4):1425-1429.
Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V:
Interferon alpha for the adjuvant treatment of cutaneous melanoma
.
Cochrane Database Syst Rev
2013(6):CD008955.
Zhao X, Suryawanshi S, Hruska M, Feng Y, Wang X, Shen J, Vezina HE, McHenry MB, Waxman IM, Achanta A
et al
:
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
.
Ann Oncol
2017,
28
(8):2002-2008.
Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A
et al
:
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
.
Ann Oncol
2018,
29
(11):2208-2213.
Barth A, Morton DL:
The role of adjuvant therapy in melanoma management
.
Cancer
1995,
75
(2 Suppl):726-734.
Chiarion-Sileni V, Del Bianco P, Romanini A, Guida M, Paccagnella A, Dalla Palma M, Naglieri E, Ridolfi R, Silvestri B, Michiara M
et al
:
Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]
.
BMC Cancer
2006,
6
:44.
Gogas H, Bafaloukos D, Ioannovich J, Skarlos D, Polyzos A, Fountzilas G, Kalofonos HP, Aravantinos G, Tsoutsos D, Panagiotou P
et al
:
Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study
.
Anticancer Res
2004,
24
(3b):1947-1952.
Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dreno B, Kirkwood JM:
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion
.
Cancer
2008,
112
(5):982-994.
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN
et al
:
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
.
Semin Radiat Oncol
2003,
13
(3):176-181.
Mohr P, Hauschild A, Enk A, Trefzer U, Rass K, Grabbe S, Brockmeyer NH, Koller J, Gogas H, Weichenthal M:
Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408).
J Clin Oncol
2008,
26
(suppl.).
Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, Bufalino R, Cascinelli N, Cocconi G, Durand J
et al
:
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma
.
N Engl J Med
1982,
307
(15):913-916.
Balch CM, Murray D, Presant C, Bartolucci AA:
Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma
.
Surgery
1984,
95
(4):454-459.
Tranum BL, Dixon D, Quagliana J, Neidhart J, Balcerzak SP, Costanzi JH, Fabian CJ, Neilan B, Maloney T, O"Bryan RM
et al
:
Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study
.
Cancer Treat Rep
1987,
71
(6):643-644.
Saba HI, Cruse CW, Wells KE, Klein CJ, Reintgen DS:
Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study
.
Ann Plast Surg
1992,
28
(1):60-64.
Stables GI, Doherty VR, MacKie RM:
Nine years" experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma
.
Br J Dermatol
1992,
127
(5):505-508.
Karakousis C, Blumenson L:
Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma
.
Eur J Cancer
1993,
29A
(13):1831-1835.
Pectasides D, Alevizakos N, Bafaloukos D, Tzonou A, Asimakopoulos G, Varthalitis I, Dimitriadis M, Athanassiou A:
Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma
.
Am J Clin Oncol
1994,
17
(1):55-59.
Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, Stadler R, Weichenthal M, Eigentler T, Ellwanger U
et al
:
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
.
Ann Oncol
2008,
19
(6):1195-1201.
Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D, Marsden J, Schadendorf D, Eggermont AM:
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis
.
Eur J Cancer
2004,
40
(3):390-402.
Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Philips D, Broeks A
et al
:
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
.
Nat Med
2018,
24
(11):1655-1661.
Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E
et al
:
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
.
Nat Med
2018,
24
(11):1649-1654.
Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H
et al
:
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
.
Lancet Oncol
2019,
20
(7):948-960.
Topalian SL, Taube JM, Pardoll DM:
Neoadjuvant checkpoint blockade for cancer immunotherapy
.
Science
2020,
367
(6477).
Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE
et al
:
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
.
Nat Med
2021,
27
(2):301-309.
Witt RG, Erstad DJ, Wargo JA:
Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials
.
Ther Adv Med Oncol
2022,
14
:17588359221083052.
Patel S, Othus M, Prieto V, Lowe M, Buchbinder E, Chen Y, Hyngstrom J, Lao CD, Truong T-G, Chandra S
et al
:
Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
.
Annals of Oncology
2022,
33
:S808-S869.
Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L
et al
:
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
.
Nat Med
2019,
25
(3):454-461.
Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ
et al
:
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma
.
Ann Oncol
2020,
31
(11):1569-1579.
Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI
et al
:
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
.
Ann Oncol
2018,
29
(8):1861-1868.
Blank CU, Reijers ILM, Saw RPM, Versluis JM, Pennington T, Kapiteijn E, Veldt AAMVD, Suijkerbuijk K, Hospers G, Houdt WJv
et al
:
Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma
.
Journal of Clinical Oncology
2022,
40
(16_suppl):9501-9501.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP:
Toxicity and response criteria of the Eastern Cooperative Oncology Group
.
Am J Clin Oncol
1982,
5
(6):649-655.
Simmons C, McMillan DC, Tuck S, Graham C, McKeown A, Bennett M, O"Neill C, Wilcock A, Usborne C, Fearon KC
et al
:
"How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer
.
Oncologist
2019.
Tse A, Verkhivker GM:
Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways
.
PLoS One
2016,
11
(11):e0166583.
Zhang C, Spevak W, Zhang Y, Burton EA, Ma Y, Habets G, Zhang J, Lin J, Ewing T, Matusow B
et al
:
RAF inhibitors that evade paradoxical MAPK pathway activation
.
Nature
2015,
526
(7574):583-586.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P
et al
:
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
.
N Engl J Med
2015,
373
(1):23-34.
Weber JS, D"Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Jr., Lao CD
et al
:
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
.
Lancet Oncol
2015,
16
(4):375-384.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M
et al
:
Pembrolizumab versus Ipilimumab in Advanced Melanoma
.
N Engl J Med
2015,
372
(26):2521-2532.
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC
et al
:
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
.
Lancet
2014,
384
(9948):1109-1117.
Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS
et al
:
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
.
JAMA
2016,
315
(15):1600-1609.
Larkin J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J, Cowey CL, Lao CD, Schadendorf D, Ferrucci PF, Smylie M
et al
:
Overall Survival Results From a Phase III Trial of Nivolumab Combined With Ipilimumab in Treatment-naïve Patients With Advanced Melanoma (CheckMate 067)
. In:
AACR Annual Meeting: April 1-5 2017; Walter E. Washington Convention Center, Washington, D.C., USA
; 2017.
Liu M, Yang X, Liu J, Zhao B, Cai W, Li Y, Hu D:
Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials
.
Oncotarget
2017,
8
(19):32258-32269.
Hao C, Tian J, Liu H, Li F, Niu H, Zhu B:
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
.
Medicine (Baltimore)
2017,
96
(26):e7325.
Atkins MB, Lee SJ, Chmielowski B, Ribas A, Tarhini AA, Truong T-G, Davar D, O"Rourke MA, Curti BD, Brell JM
et al
:
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134
.
Journal of Clinical Oncology
2021,
39
(36_suppl):356154-356154.
Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsova I, Liszkay G
et al
:
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma
.
J Clin Oncol
2022:JCO2102659.
Gogas H, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R
et al
:
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)
.
Eur J Cancer
2021,
152
:116-128.
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R
et al
:
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
.
Lancet Oncol
2018,
19
(10):1315-1327.
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R
et al
:
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
.
Lancet Oncol
2018,
19
(5):603-615.
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT
et al
:
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
.
N Engl J Med
2012,
366
(8):707-714.
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA
et al
:
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
.
Lancet Oncol
2014,
15
(3):323-332.
Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A
et al
:
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
.
Lancet Oncol
2012,
13
(11):1087-1095.
Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A
et al
:
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
.
J Am Acad Dermatol
2014,
71
(6):1102-1109 e1101.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M
et al
:
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
.
Eur J Cancer
2009,
45
(2):228-247.
Miller AB, Hoogstraten B, Staquet M, Winkler A:
Reporting results of cancer treatment
.
Cancer
1981,
47
(1):207-214.
Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD:
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials
.
JAMA Oncol
2015,
1
(4):433-440.
Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J
et al
:
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma
.
Eur J Cancer
2019,
116
:207-215.
Modification of the Dosage Regimen for Nivolumab
[
http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm
]
Fogt S, Shustova M, Demidov LV, Moiseyenko V, Tjulandin S, Semiglazova T, Protsenko S, Odintsova S, Zukov R, Lazarev S
et al
:
Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma
.
Journal of Clinical Oncology
2019,
37
(15_suppl):9549-9549.
Tjulandin S, Fedyanin M, Demidov L, Moiseyenko V, Protsenko S, Odintsova S, Semiglazova TY, Zukov R, Lazarev S, Andreev A
et al
:
FINAL RESULTS OF PHASE II TRIAL (MIRACULUM) OF THE NOVEL PD-1 INHIBITOR PROLGOLIMAB IN PATIENTS WITH ADVANCED MELANOMA
.
Annals of Oncology
2019,
30
:xi33-xi47.
Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA
et al
:
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
.
Lancet Oncol
2018,
19
(5):672-681.
Lebbe C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M
et al
:
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
.
J Clin Oncol
2019,
37
(11):867-875.
Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E
et al
:
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
.
J Clin Oncol
2021,
39
(24):2647-2655.
Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF
et al
:
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
.
Cancer Res
2010,
70
(13):5518-5527.
Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R
et al
:
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
.
Eur J Cancer
2015,
51
(18):2792-2799.
Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C
et al
:
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
.
Eur J Cancer
2017,
75
:47-55.
Hodi FS, O"Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC
et al
:
Improved survival with ipilimumab in patients with metastatic melanoma
.
N Engl J Med
2010,
363
(8):711-723.
Robert C, Thomas L, Bondarenko I, O"Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ
et al
:
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
.
N Engl J Med
2011,
364
(26):2517-2526.
Самойленко ИВ, Харкевич ГЮ, Демидов ЛВ:
ПРИМЕНЕНИЕ БЛОКАТОРА РЕЦЕПТОРОВ CTLA4 В ЛЕЧЕНИИ БОЛЬНЫХ МЕТАСТАТИЧЕСКОЙ МЕЛАНОМОЙ
.
РОССИЙСКИЙ МЕДИЦИНСКИЙ ЖУРНАЛ
2015,
21
(1):4-9.
Li J, Gu J:
Efficacy and safety of ipilimumab for treating advanced melanoma: A systematic review and meta-analysis
.
J Clin Pharm Ther
2019,
44
(3):420-429.
Zhang S, Liang F, Li W, Wang Q:
Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis
.
Eur J Cancer
2017,
83
:71-79.
Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L
et al
:
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
.
Lancet
2020,
395
(10240):1835-1844.
Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Stephens R, Svane IM
et al
:
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
.
J Immunother Cancer
2020,
8
(2).
Yi JH, Yi SY, Lee HR, Lee SI, Lim DH, Kim JH, Park KW, Lee J:
Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia
.
Melanoma Res
2011,
21
(3):223-227.
Serrone L, Zeuli M, Sega FM, Cognetti F:
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
.
J Exp Clin Cancer Res
2000,
19
(1):21-34.
Hill GJ, 2nd, Krementz ET, Hill HZ:
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)
.
Cancer
1984,
53
(6):1299-1305.
Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A
et al
:
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
.
J Clin Oncol
2000,
18
(1):158-166.
МАНЗЮК Л, БОРОДКИНА А, АРТАМОНОВА Е, НАДЕЖДИНА Т, ТОКАРЕВА З, ХАЛЯСТОВ И:
Опыт применения лекарственных комбинаций на основе аранозы при лечении диссеминированной меланомы кожи
.
Вестник РОНЦ им Н Н Блохина РАМН
2000,
11
(2):4.
Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J
et al
:
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
.
J Clin Oncol
2009,
27
(17):2823-2830.
Samoylenko I, Kharkevich G, Petenko NN, Orlova K, Sinelnikov I, Utyashev I, Vikhrova A, Markina I, Demidov L:
Paclitaxel and carboplatin chemotherapy in patients with metaststic melanoma refractory to BRAF/MEK inhibitors
.
J Clin Oncol
2016,
34
:No 15_suppl (May 20 Supplement), 2016: 9552.
Ives NJ, Stowe RL, Lorigan P, Wheatley K:
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients
.
J Clin Oncol
2007,
25
(34):5426-5434.
Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM, Eastern Cooperative Oncology G:
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group
.
J Clin Oncol
2008,
26
(35):5748-5754.
Carbone PP, Costello W:
Eastern Cooperative Oncology Group studies with DTIC (NSC-45388)
.
Cancer Treat Rep
1976,
60
(2):193-198.
Nashan D, Muller ML, Grabbe S, Wustlich S, Enk A:
Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine
.
J Eur Acad Dermatol Venereol
2007,
21
(10):1305-1318.
Larkin JM, Hughes SA, Beirne DA, Patel PM, Gibbens IM, Bate SC, Thomas K, Eisen TG, Gore ME:
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma
.
Br J Cancer
2007,
96
(1):44-48.
Ahmann DL, Hahn RG, Bisel HF:
A Comparative Study of 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and Imidazole Carboxamide (NSC 45388) with Vincristine (NSC 67574) in the Palliation of Disseminated Malignant Melanoma
.
Cancer Research
1972,
32
(11):2432-2434.
Hill GJ, 2nd, Ruess R, Berris R, Philpott GW, Parkin P:
Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU)
.
Ann Surg
1974,
180
(2):167-174.
Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ
et al
:
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial
.
J Clin Oncol
2002,
20
(8):2045-2052.
Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM:
Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
.
Journal of Clinical Oncology
2013,
31
(3):373-379.
Larkin J, Minor D, D"Angelo S, Neyns B, Smylie M, Miller WH, Jr., Gutzmer R, Linette G, Chmielowski B, Lao CD
et al
:
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator"s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
.
J Clin Oncol
2017:JCO2016718023.
Gurney H:
How to calculate the dose of chemotherapy
.
Br J Cancer
2002,
86
(8):1297-1302.
de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJ, Planting AS, Nooter K, Stoter G, Sparreboom A:
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure
.
J Clin Oncol
2001,
19
(17):3733-3739.
Da Silva IP, Ahmed T, Lo S, Reijers ILM, Weppler A, Warner AB, Patrinely JR, Serra-Bellver P, Lebbe C, Mangana J
et al
:
Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.
J Clin Oncol
2020,
38
.
Arance AM, Cruz-Merino Ldl, Petrella TM, Jamal R, Ny L, Carneiro A, Berrocal A, Marquez-Rodas I, Spreafico A, Atkinson V
et al
:
Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004
.
Journal of Clinical Oncology
2021,
39
(15_suppl):9504-9504.
Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA
et al
:
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
.
Eur J Cancer
2018,
91
:116-124.
Schreuer M, Jansen Y, Planken S, Chevolet I, Seremet T, Kruse V, Neyns B:
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial
.
Lancet Oncol
2017,
18
(4):464-472.
Scholtens A, Geukes Foppen MH, Blank CU, van Thienen JV, van Tinteren H, Haanen JB:
Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression
.
Eur J Cancer
2015,
51
(5):642-652.
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS
et al
:
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
.
N Engl J Med
2015,
372
(21):2006-2017.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS
et al
:
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
.
N Engl J Med
2013,
369
(2):134-144.
Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A, Keikavoussi P, Becker JC, Rittgen W, Hochhaus A
et al
:
Lack of clinical efficacy of imatinib in metastatic melanoma
.
Br J Cancer
2005,
92
(8):1398-1405.
Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA:
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy
.
Cancer
2006,
106
(9):2005-2011.
D"Angelo SP, Larkin J, Sosman JA, Lebbe C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P
et al
:
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
.
J Clin Oncol
2017,
35
(2):226-235.
Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ
et al
:
The efficacy of anti-PD-1 agents in acral and mucosal melanoma
.
Cancer
2016,
122
(21):3354-3362.
Weichenthal M, Ugurel S, Leiter UM, Satzger I, Kähler KC, Welzel J, Pföhler C, Feldmann-Böddeker I, Meier FE, Terheyden P
et al
:
Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry
.
Journal of Clinical Oncology
2019,
37
(15_suppl):9505-9505.
Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL, Jr., Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L
et al
:
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
.
Lancet Oncol
2016,
17
(7):943-955.
Reschke R, Ziemer M:
Rechallenge with checkpoint inhibitors in metastatic melanoma
.
J Dtsch Dermatol Ges
2020,
18
(5):429-436.
Wolchok JD, Hoos A, O"Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G
et al
:
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
.
Clin Cancer Res
2009,
15
(23):7412-7420.
Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS:
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements
.
Clin Cancer Res
2013,
19
(14):3936-3943.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A
et al
:
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
.
Lancet Oncol
2017,
18
(3):e143-e152.
Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M
et al
:
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
.
Lancet Oncol
2019,
20
(9):1239-1251.
Martinez SR, Young SE:
A rational surgical approach to the treatment of distant melanoma metastases
.
Cancer Treat Rev
2008,
34
(7):614-620.
Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, Liu PY, Unger JM, Flaherty LE, Sondak VK:
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430
.
Cancer
2011,
117
(20):4740-4706.
Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, Sondak VK, Reintgen DS, Kashani-Sabet M, Karakousis CP
et al
:
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)
.
Ann Surg Oncol
2012,
19
(8):2547-2555.
Blankenstein SE, Aarts MJB, van den Berkmortel F, Boers-Sonderen M, van den Eertwegh AJM, Franken MG, de Groot JW, Haanen JBAG, Hospers G, Kapiteijn E
et al
:
Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy
.
J Clin Oncol
2020,
38
.
Leung AM, Hari DM, Morton DL:
Surgery for distant melanoma metastasis
.
Cancer J
2012,
18
(2):176-184.
Creech O, Jr., Ryan RF, Krementz ET:
Treatment of melanoma by isolation-perfusion technique
.
J Am Med Assoc
1959,
169
(4):339-343.
Thompson JF, Lai DT, Ingvar C, Kam PC:
Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma
.
Melanoma Res
1994,
4 Suppl 1
:45-50.
Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A:
Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety
.
Oncologist
2010,
15
(4):416-427.
Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM, 3rd, Alexander HR
et al
:
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020
.
J Clin Oncol
2006,
24
(25):4196-4201.
Hyde MA, Hadley ML, Tristani-Firouzi P, Goldgar D, Bowen GM:
A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions
.
Arch Dermatol
2012,
148
(5):592-596.
Cotter MA, McKenna JK, Bowen GM:
Treatment of lentigo maligna with imiquimod before staged excision
.
Dermatol Surg
2008,
34
(2):147-151.
Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, Haque R, Odom C, Jankey C, Cornelison RL:
Treatment of lentigo maligna with topical imiquimod
.
Br J Dermatol
2003,
149 Suppl 66
:66-70.
Youland RS, Blanchard ML, Dronca R, Kottschade L, Markovic SN, Olivier KR, Park SS:
Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era
.
Clin Transl Radiat Oncol
2017,
6
:25-30.
Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, Urban A, Schell H, Hohenberger W, Sauer R:
Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience
.
Int J Radiat Oncol Biol Phys
1999,
44
(3):607-618.
McQuay HJ, Collins SL, Carroll D, Moore RA:
Radiotherapy for the palliation of painful bone metastases
.
The Cochrane database of systematic reviews
2000(2):CD001793.
Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V
et al
:
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
.
J Clin Oncol
2022,
40
(5):492-516.
Gondi V, Bauman G, Bradfield L, Burri SH, Cabrera AR, Cunningham DA, Eaton BR, Hattangadi-Gluth JA, Kim MM, Kotecha R
et al
:
Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline
.
Pract Radiat Oncol
2022,
12
(4):265-282.
Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, Galldiks N, de Azambuja E, Berghoff AS, Metellus P
et al
:
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
.
Ann Oncol
2021,
32
(11):1332-1347.
Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, Kirkwood JM, Tarhini A, Moschos S, Lunsford LD:
Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article
.
J Neurosurg
2011,
114
(3):769-779.
Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, Lawson D, Dutcher JP, Weiss G, Curti B
et al
:
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study
.
Cancer
2008,
113
(8):2139-2145.
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S
et al
:
Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient
.
Journal of Clinical Oncology
2020,
38
(32):3773-3784.
Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA
et al
:
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
.
N Engl J Med
2018,
379
(8):722-730.
Komori T, Otsuka A, Kusuba N, Taniguchi K, Endo Y, Honda T, Kabashima K:
Rapid regression of metastatic brain tumours in a melanoma patient after dabrafenib/trametinib therapy
.
Eur J Dermatol
2017,
27
(5):548-549.
Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L
et al
:
Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
.
Lancet Oncol
2017,
18
(7):863-873.
Dummer R, Queirolo P, Guijarro AMA, Hu Y, Wang D, Azevedo SJ, Robert C, Ascierto PA, -Sileni VC, Pronzato P
et al
:
Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study
.
Journal of Clinical Oncology
2022,
40
(16_suppl):9515-9515.
Zhuang H, Shi S, Yuan Z, Chang JY:
Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues
.
Mol Cancer
2019,
18
(1):21.
Khan M, Zhao Z, Arooj S, Liao G:
Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis
.
BMC Cancer
2021,
21
(1):167.
Boothe D, Young R, Yamada Y, Prager A, Chan T, Beal K:
Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery
.
Neuro Oncol
2013,
15
(9):1257-1263.
Lopetegui-Lia N, Dima D, Osantowski B, Davis R, Song JM, McNamara MJ, Suh JH, Chao ST, Funchain P, Kennedy LB:
Bevacizumab for radiation necrosis of the brain or steroid-refractory edema in patients with melanoma receiving immune checkpoint inhibitors
.
Journal of Clinical Oncology
2022,
40
(16_suppl):e14008-e14008.
Jessurun CAC, Hulsbergen AFC, de Wit AE, Tewarie IA, Snijders TJ, Verhoeff JJC, Phillips JG, Reardon DA, Mekary RA, Broekman MLD:
The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis
.
Neuro Oncol
2021,
23
(8):1261-1272.
Kroeze SG, Fritz C, Hoyer M, Lo SS, Ricardi U, Sahgal A, Stahel R, Stupp R, Guckenberger M:
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review
.
Cancer Treat Rev
2017,
53
:25-37.
Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, Andtbacka RH, Noyes RD, Shrieve DC, Grossmann KF:
Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma
.
J Clin Oncol
2013,
31
(17):e283-287.
Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM:
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)
.
Int J Radiat Oncol Biol Phys
2016,
95
(2):632-646.
Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, Spektor A, Krishnan M, Ott PA, Balboni TA
et al
:
Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
.
Int J Radiat Oncol Biol Phys
2017,
98
(2):344-351.
Trapani S, Manicone M, Sikokis A, D"Abbiero N, Salaroli F, Ceccon G, Buti S:
Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review
.
Crit Rev Oncol Hematol
2019,
142
:9-15.
Tsui JM, Mihalcioiu C, Cury FL:
Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab
.
Cureus
2018,
10
(2):e2238.
Bei D, Osawa M, Uemura S, Ohno T, Gobburu J, Roy A, Hasegawa M:
Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers
.
Cancer Sci
2020,
111
(2):528-535.
Bianconi C, Gandini G, Zanotti G, Dall’Ara M, Sterzi E, Barbazza R, Marini P:
3PC-020 Nivolumab weight-based dosing vs flat dose economic analysis
.
European Journal of Hospital Pharmacy
2019,
26
(Suppl 1):A45-A46.
Schadendorf D, Hassel JC, Fluck M, Eigentler T, Loquai C, Berneburg M, Gutzmer R, Meier F, Mohr P, Hauschild A
et al
:
Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED), LBA67
.
Ann Oncol
2019,
30
(suppl.5):903-904.
Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry Dt, Holly EA, Sagebiel RW, Potischman N:
Diet and melanoma in a case-control study
.
Cancer Epidemiol Biomarkers Prev
2004,
13
(6):1042-1051.
Silver JK, Baima J:
Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes
.
Am J Phys Med Rehabil
2013,
92
(8):715-727.
Nilsson H, Angeras U, Bock D, Borjesson M, Onerup A, Fagevik Olsen M, Gellerstedt M, Haglind E, Angenete E:
Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer
.
BMJ open
2016,
6
(1):e007997.
Siegel GW, Biermann JS, Chugh R, Jacobson JA, Lucas D, Feng M, Chang AC, Smith SR, Wong SL, Hasen J:
The multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework
.
J Multidiscip Healthc
2015,
8
:109-115.
Shehadeh A, El Dahleh M, Salem A, Sarhan Y, Sultan I, Henshaw RM, Aboulafia AJ:
Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients" outcome
.
Hematol Oncol Stem Cell Ther
2013,
6
(3-4):105-111.
Cox CL, Montgomery M, Oeffinger KC, Leisenring W, Zeltzer L, Whitton JA, Mertens AC, Hudson MM, Robison LL:
Promoting physical activity in childhood cancer survivors: results from the Childhood Cancer Survivor Study
.
Cancer
2009,
115
(3):642-654.
Field T:
Massage therapy research review
.
Complement Ther Clin Pract
2016,
24
:19-31.
Tantawy SA, Abdelbasset WK, Nambi G, Kamel DM:
Comparative Study Between the Effects of Kinesio Taping and Pressure Garment on Secondary Upper Extremity Lymphedema and Quality of Life Following Mastectomy: A Randomized Controlled Trial
.
Integr Cancer Ther
2019,
18
:1534735419847276.
Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI, Committee EG:
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
.
Ann Oncol
2018,
29
(Suppl 4):iv166-iv191.
Oren R, Zagury Al, Katzir O, Kollender Y, Meller I:
Musculoskeletal Cancer Surgery
. In
.
, edn. Edited by Malawer. Dordrecht: Springer; 2013: 583-593.
Committee. NMA:
Topic: The Diagnosis and Treatment of Lymphedema. Position Statement of the National Lymphedema Network.
. In
.
; 2011: 1-19.
Baxter GD, Liu L, Petrich S, Gisselman AS, Chapple C, Anders JJ, Tumilty S:
Low level laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review
.
BMC Cancer
2017,
17
(1):833.
Segal R, Zwaal C, Green E, Tomasone JR, Loblaw A, Petrella T, Exercise for People with Cancer Guideline Development G:
Exercise for people with cancer: a systematic review
.
Curr Oncol
2017,
24
(4):e290-e315.
Boyd C, Crawford C, Paat CF, Price A, Xenakis L, Zhang W, Evidence for Massage Therapy Working G:
The Impact of Massage Therapy on Function in Pain Populations-A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part II, Cancer Pain Populations
.
Pain Med
2016,
17
(8):1553-1568.
Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J:
A Systematic Review of Exercise Systematic Reviews in the Cancer Literature (2005-2017)
.
PM R
2017,
9
(9S2):S347-S384.
Hu M, Lin W:
Effects of exercise training on red blood cell production: implications for anemia
.
Acta Haematol
2012,
127
(3):156-164.
Bland KA, Zadravec K, Landry T, Weller S, Meyers L, Campbell KL:
Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research
.
Crit Rev Oncol Hematol
2019,
136
:79-85.
Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, Mohr D, Palesh OG, Peppone LJ, Piper BF
et al
:
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis
.
JAMA Oncol
2017,
3
(7):961-968.
Kinkead B, Schettler PJ, Larson ER, Carroll D, Sharenko M, Nettles J, Edwards SA, Miller AH, Torres MA, Dunlop BW
et al
:
Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial
.
Cancer
2018,
124
(3):546-554.
Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, Gollhofer A, Bloch W, Baumann FT:
Exercise intervention studies in patients with peripheral neuropathy: a systematic review
.
Sports Med
2014,
44
(9):1289-1304.
Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, Fung C, Janelsins MC, Asare M, Lin PJ
et al
:
Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial
.
Support Care Cancer
2018,
26
(4):1019-1028.
Lee JM, Look RM, Turner C, Gardiner SK, Wagie T, Douglas J, Sorenson L, Evans L, Kirchner S, Dashkoff C
et al
:
Low-level laser therapy for chemotherapy-induced peripheral neuropathy
.
Journal of Clinical Oncology
2012,
30
(15_suppl):9019-9019.
Rick O, von Hehn U, Mikus E, Dertinger H, Geiger G:
Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study
.
Bioelectromagnetics
2017,
38
(2):85-94.
Kilinc M, Livanelioglu A, Yildirim SA, Tan E:
Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain
.
J Rehabil Med
2014,
46
(5):454-460.
Oberoi S, Zamperlini-Netto G, Beyene J, Treister NS, Sung L:
Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis
.
PLoS One
2014,
9
(9):e107418.
Ross M, Fischer-Cartlidge E:
Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia
.
Clin J Oncol Nurs
2017,
21
(2):226-233.
Kessels E, Husson O, van der Feltz-Cornelis CM:
The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis
.
Neuropsychiatr Dis Treat
2018,
14
:479-494.
Rief H, Omlor G, Akbar M, Welzel T, Bruckner T, Rieken S, Haefner MF, Schlampp I, Gioules A, Habermehl D
et al
:
Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial
.
BMC Cancer
2014,
14
:67.
Bensadoun RJ, Nair RG:
Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy
.
Photomed Laser Surg
2015,
33
(10):487-491.
Temoshok L:
Biopsychosocial studies on cutaneous malignant melanoma: psychosocial factors associated with prognostic indicators, progression, psychophysiology and tumor-host response
.
Soc Sci Med
1985,
20
(8):833-840.
Dirksen SR:
Perceived well-being in malignant melanoma survivors
.
Oncol Nurs Forum
1989,
16
(3):353-358.
Lichtenthal WG, Cruess DG, Schuchter LM, Ming ME:
Psychosocial factors related to the correspondence of recipient and provider perceptions of social support among patients diagnosed with or at risk for malignant melanoma
.
J Health Psychol
2003,
8
(6):705-719.
Sollner W, Zschocke I, Zingg-Schir M, Stein B, Rumpold G, Fritsch P, Augustin M:
Interactive patterns of social support and individual coping strategies in melanoma patients and their correlations with adjustment to illness
.
Psychosomatics
1999,
40
(3):239-250.
Devine D, Parker PA, Fouladi RT, Cohen L:
The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment
.
Psychooncology
2003,
12
(5):453-462.
Folkman S, Lazarus RS, Gruen RJ, DeLongis A:
Appraisal, coping, health status, and psychological symptoms
.
J Pers Soc Psychol
1986,
50
(3):571-579.
Беляев АМ, Чулкова ВА, Семиглазова ТЮ, Рогачев МВ (eds.):
Онкопсихология для врачей-онкологов и медицинских психологов. Руководство
. СПб: Любавич; 2017.
Fawzy FI, Cousins N, Fawzy NW, Kemeny ME, Elashoff R, Morton D:
A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance
.
Arch Gen Psychiatry
1990,
47
(8):720-725.
Holland JC, Passik S, Kash KM, Russak SM, Gronert MK, Sison A, Lederberg M, Fox B, Baider L:
The role of religious and spiritual beliefs in coping with malignant melanoma
.
Psychooncology
1999,
8
(1):14-26.
Baider L, Perry S, Sison A, Holland J, Uziely B, DeNour AK:
The role of psychological variables in a group of melanoma patients. An Israeli sample
.
Psychosomatics
1997,
38
(1):45-53.
Lehto US, Ojanen M, Kellokumpu-Lehtinen P:
Predictors of quality of life in newly diagnosed melanoma and breast cancer patients
.
Ann Oncol
2005,
16
(5):805-816.
Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, Morton DL:
Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later
.
Arch Gen Psychiatry
1993,
50
(9):681-689.
Fawzy FI, Kemeny ME, Fawzy NW, Elashoff R, Morton D, Cousins N, Fahey JL:
A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures
.
Arch Gen Psychiatry
1990,
47
(8):729-735.
Fawzy FI, Canada AL, Fawzy NW:
Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up
.
Arch Gen Psychiatry
2003,
60
(1):100-103.
Boesen EH, Boesen SH, Frederiksen K, Ross L, Dahlstrom K, Schmidt G, Naested J, Krag C, Johansen C:
Survival after a psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study
.
J Clin Oncol
2007,
25
(36):5698-5703.
Boesen EH, Ross L, Frederiksen K, Thomsen BL, Dahlstrom K, Schmidt G, Naested J, Krag C, Johansen C:
Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study
.
J Clin Oncol
2005,
23
(6):1270-1277.
McLoone J, Menzies S, Meiser B, Mann GJ, Kasparian NA:
Psycho-educational interventions for melanoma survivors: a systematic review
.
Psychooncology
2013,
22
(7):1444-1456.
Sample A, He YY:
Mechanisms and prevention of UV-induced melanoma
.
Photodermatol Photoimmunol Photomed
2018,
34
(1):13-24.
Craig S, Earnshaw CH, Viros A:
Ultraviolet light and melanoma
.
J Pathol
2018,
244
(5):578-585.
Runger TM:
Mechanisms of Melanoma Promotion by Ultraviolet Radiation
.
J Invest Dermatol
2016,
136
(9):1751-1752.
Green AC, Williams GM, Logan V, Strutton GM:
Reduced melanoma after regular sunscreen use: randomized trial follow-up
.
J Clin Oncol
2011,
29
(3):257-263.
Ghiasvand R, Weiderpass E, Green AC, Lund E, Veierod MB:
Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study
.
J Clin Oncol
2016,
34
(33):3976-3983.
Dessinioti C, Geller AC, Stergiopoulou A, Swetter SM, Baltas E, Mayer JE, Johnson TM, Talaganis J, Trakatelli M, Tsoutsos D
et al
:
Association of Skin Examination Behaviors and Thinner Nodular vs Superficial Spreading Melanoma at Diagnosis
.
JAMA Dermatol
2018,
154
(5):544-553.
Kasparian NA, Branstrom R, Chang YM, Affleck P, Aspinwall LG, Tibben A, Azizi E, Baron-Epel O, Battistuzzi L, Bruno W
et al
:
Skin examination behavior: the role of melanoma history, skin type, psychosocial factors, and region of residence in determining clinical and self-conducted skin examination
.
Arch Dermatol
2012,
148
(10):1142-1151.
Titus LJ, Clough-Gorr K, Mackenzie TA, Perry A, Spencer SK, Weiss J, Abrahams-Gessel S, Ernstoff MS:
Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth
.
Br J Dermatol
2013,
168
(3):571-576.
Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P
et al
:
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma"
.
J Dtsch Dermatol Ges
2013,
11 Suppl 6
:1-116, 111-126.
DeRose ER, Pleet A, Wang W, Seery VJ, Lee MY, Renzi S, Sullivan RJ, Atkins MB:
Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma
.
Melanoma Res
2011,
21
(4):364-369.
Schneider J:
The teaspoon rule of applying sunscreen
.
Arch Dermatol
2002,
138
(6):838-839.
Karnofsky DA, Burchenal JH:
The clinical evaluation of chemotherapeutic agents in cancer
. In:
Evaluation of chemotherapeutic agents.
edn. Edited by MacLeod C. New York: Columbia University Press; 1949: 191-205.
Гомболевский ВА, Лайпан АШ, Шапиев АН, Владзимирский АВ, Морозов СП (eds.):
Методические рекомендации по применению критериев ответа солидных опухолей на химиотерапевтическое лечение (RECIST 1.1). Методические рекомендации №46
; 2018.
Для продолжения работы требуется
Регистрация
Предыдущая страница
Следующая страница
Оглавление
Список сокращений
Термины и определения
Меланома кожи и слизистых оболочек
+
Список литературы
Приложение А1. Состав рабочей группы
Приложение А2. Методология разработки клинических рекомендаций
Приложение А3. Связанные документы
Приложение Б. Алгоритмы ведения пациента
Приложение В. Информация для пациентов
Приложение Г1-ГN. Шкалы оценки, вопросники и другие оценочные инструменты состояния пациента, приведенные в клинических рекомендациях
+
Данный блок поддерживает скрол*